Related Experiment Videos
Calcium antagonists in the elderly. A risk-benefit analysis
1Division of Geriatric Medicine, Northwestern University Medical School, Chicago, Illinois, USA. jbs157@nwu.edu
Drugs & Aging
|July 1, 1996
Summary
Calcium antagonists effectively manage blood pressure and angina in patients of all ages. However, aging reduces drug clearance, potentially increasing adverse effects and necessitating dosage adjustments in older adults.
Area of Science:
- Cardiology
- Pharmacology
- Geriatrics
Background:
- Calcium antagonists are widely used for hypertension and angina.
- Aging affects drug clearance and patient sensitivity to medications.
- Dosage standardization across age groups in clinical trials complicates sensitivity analysis.
Purpose of the Study:
- To evaluate the efficacy and safety of calcium antagonists in older versus younger patients.
- To identify age-related differences in calcium antagonist pharmacokinetics and pharmacodynamics.
- To inform optimal therapeutic strategies for elderly individuals.
Main Methods:
- Review of clinical trials comparing calcium antagonist efficacy and safety in different age groups.
- Analysis of pharmacokinetic data regarding drug clearance in aging populations.
- Comparison of blood pressure and heart rate responses to standard dosages.
Main Results:
- Reduced drug clearance with aging necessitates dosage adjustments.
- Older patients exhibit greater blood pressure reduction and heart rate suppression.
- Verapamil, but not dihydropyridines, reduced mortality post-myocardial infarction.
- Increased risk of adverse effects and drug interactions in the elderly.
Conclusions:
- Calcium antagonists require careful dosing in older adults due to altered pharmacokinetics.
- While beneficial for symptoms, long-term benefits in elderly hypertension are unproven.
- Verapamil shows specific mortality benefits post-myocardial infarction.
- Elderly patients face higher risks of adverse events and interactions.